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Serotonin reverts age-related capillarization and failure of
regeneration in the liver through a VEGF-dependent pathway.
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Abstract: The function of the liver is well-preserved during the aging
process, although some evidence suggests that liver regeneration
might be impaired with advanced age. We observed a decreased abil-
ity of the liver to restore normal volume after partial hepatectomy in
elderly mice, and we identiﬁed a pathway that rescued regeneration
and was triggered by serotonin. 2,5-dimethoxy-4-iodoamphetamine
(DOI), a serotonin receptor agonist, reversed the age-related pseudo-
capillarization of old liver and improved hepatosinusoidal blood
ﬂow. After hepatectomy, the open fenestrae were associated with a
restored attachment of platelets to endothelium and the initiation
of a normal regenerative response, including the up-regulation of
essential growth mediators and serotonin receptors. In turn, hepato-
cyte proliferation recovered along with regain of liver volume and
animal survival. DOI operates through the release of VEGF, and its
effects could be blocked with anti-VEGF antibodies both in vitro
and in vivo. These results suggest that pseudocapillarization in the
aged acts as a barrier to liver regeneration. DOI breaks this restraint
through an endothelium-dependent mechanism driven by VEGF. This
pathway highlights a target for reversing the age-associated decline
in the capacity of the liver to regenerate.
 2011 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.The liver is a remarkable organ which can regenerate after major
surgery or injury in the adult. In a previous study the group from
Zurich headed by Professor Pierre Alain-Clavien published aJournal of Hepatology 20
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blood borne platelets [1]. Serotonin was found to act through
receptors expressed by liver tissue and mice with impaired plate-
let responses had defective liver regeneration. Treatment of these
mice with a serotonin agonist ‘rescued’ this deﬁciency and
allowed liver regeneration to occur. These novel observations
lead to the possibility that therapeutic treatment with serotonin
receptor agonists might be a possible strategy to augment liver
regeneration.
In their most recent paper published in PNAS, the Zurich group
have gone on to study the effect of aging on serotonin pathways
and liver regeneration. Furrer et al. elegantly demonstrate deﬁ-
cient liver regeneration in aged mice that have been subjected
to 70% hepatectomy [2]. Mechanistic insight into this observation
is provided through novel associations with failure of expression
of serotonin receptors, a loss of endothelial fenestration in the
hepatic sinusoids and increased mortality related to a failure of
hepatic regeneration. Both the inadequacy of serotonin receptor
expression and the process of loss of fenestration, termed
pseudocapillarization, is reversible by treating animals with a
serotonin receptor agonist 2,5 dimethoxy-4-iodoamphetamine
(DOI). In addition, they show that DOI affects expression of a
number of candidate mediators but has greatest effect on expres-
sion of vascular endothelial growth factor (VEGF). They further
show that DOI treated animals that are exposed to anti VEGF
antibody have a diminished regenerative response after liver
resection. Based on these observations, Furrer et al. propose a
model where loss of fenestration in aging sinusoids limits access
of regenerative molecules to hepatocytes and suggest that
DOI may reverse this process by improving fenestration via VEGF
[2].
The proposed model would certainly explain their ﬁndings
but as with many other novel studies it also raises new questions.
The purpose of fenestrations is not fully understood. Moreover,
the processes that lead to pseudocapillarization in old age also
remain obscure. In the context of the current paper the normalcy
of serotonin concentrations in aging mice and the development of
pseudocapillarization seem to partly conﬂict with the effects of
serotonin agonists in reversing pseudocapillarization in this
model. Further it would be interesting to understand the nature
of the serotonin-VEGF-fenestration axis in development or in
the livers of young animals. Data supporting a VEGF-fenestration
axis as a mechanism for the effects of serotonin or DOI are strong;
however, it is not beyond the bounds of possibility that there may11 vol. 55 j 1455–1456
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be effects on other pathways relevant to regeneration. It is known
for example that old age is associated with changes in the propor-
tion of cells at different stages in the cell cycle. Speciﬁcally, old
age is associated with fewer cells in G1/S phase and this in turn
might be associated with an impaired response to regeneration
stimuli. Serotonin is known to affect cell growth and develop-
ment; however, data on this are at times conﬂicting. It would
be interesting to know what the impact of serotonin or serotonin
agonists is on the hepatocyte cell cycle.
The study by Furrer et al. focuses on 2-year-old mice and we
cannot tell from the information given whether loss of endothe-
lial fenestration is a gradual process that continues through
adulthood and at what stage this becomes signiﬁcant in terms
of regenerative responses. Similarly, we can only estimate the
age equivalency of the 2-year-old mouse in human years. These
questions become important when we try to relate this research
to the human clinical situation. The majority of patients who
undergo liver resection in the West would be considered elderly
and yet failure of liver regeneration even after major hepatec-
tomy is rarely a clinical problem [3,4]. In a similar vein, liver
regeneration after split liver transplant or liver resection is rarely
a problem in patients with thrombocytopenia. So what exactly is
the role of platelets and serotonin in liver regeneration in man?
These questions remain unanswered however there is no doubt
that serotonin is a remarkable molecule. This molecule that is
produced largely by enterochromafﬁn cells in the gut has been
implicated in bone health [5], regulating beta cell mass in preg-
nancy [6], psychiatric disease and even as the trigger for locusts
to swarm [7].
That serotonin should be a potential target for drug develop-
ment is no surprise given the compelling data provided by the
Clavien group in their current paper published in PNAS [2] and
in previous publications [1]. In the paper by Furrer et al., DOI is
associated with increased serotonin receptor expression by hepa-
tocytes and with increased fenestration of sinusoidal endothelial
cells. Both changes could potentially affect liver regeneration but
which is more important? An alternative view would say that
since both are potentially beneﬁcial the science does not matter,
it is the effect that is important. As scientists and doctors we do1456 Journal of Hepatology 2011however, like to know these things – particularly since serotonin
agonists have been implicated in promoting ﬁbrotic responses [8]
and since VEGF inhibitors are currently in use in treating colorec-
tal cancer [9]. And so it is likely that further work will need to be
done before serotonin receptor antagonists ﬁnd their way into
the formulary of the liver surgeon.Conﬂict of interest
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